Attached files
| file | filename |
|---|---|
| 10-K - 10-K - UNITED THERAPEUTICS Corp | a2196607z10-k.htm |
| EX-21 - EX-21 - UNITED THERAPEUTICS Corp | a2196607zex-21.htm |
| EX-23.1 - EX-23.1 - UNITED THERAPEUTICS Corp | a2196607zex-23_1.htm |
| EX-31.1 - EX-31.1 - UNITED THERAPEUTICS Corp | a2196607zex-31_1.htm |
| EX-32.2 - EX-32.2 - UNITED THERAPEUTICS Corp | a2196607zex-32_2.htm |
| EX-31.2 - EX-31.2 - UNITED THERAPEUTICS Corp | a2196607zex-31_2.htm |
| EX-32.1 - EX-32.1 - UNITED THERAPEUTICS Corp | a2196607zex-32_1.htm |
| EX-10.47 - EX-10.47 - UNITED THERAPEUTICS Corp | a2196607zex-10_47.htm |
| EX-10.46 - EX-10.46 - UNITED THERAPEUTICS Corp | a2196607zex-10_46.htm |
| EX-10.48 - EX-10.48 - UNITED THERAPEUTICS Corp | a2196607zex-10_48.htm |
QuickLinks -- Click here to rapidly navigate through this document
United Therapeutics Corporation
Ratio of Earnings to Fixed Charges
(Unaudited)
| |
Year Ended December 31, | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |
2009 | 2008 | 2007 | 2006 | 2005 | |||||||||||||
| |
As adjusted (1) in thousands, except ratio |
|||||||||||||||||
Earnings: |
||||||||||||||||||
Earnings (losses) from continuing operations before income taxes |
$ | 18,767 | $ | (83,721 | ) | $ | 4,477 | $ | 37,973 | $ | 47,522 | |||||||
Add: |
||||||||||||||||||
Loss from equity investee |
141 | 226 | 321 | 491 | 754 | |||||||||||||
Fixed charges |
18,326 | 17,357 | 16,855 | 3,589 | 29 | |||||||||||||
Less: Capitalized interest |
(5,154 | ) | (4,757 | ) | (689 | ) | — | — | ||||||||||
Earnings, as adjusted |
$ | 32,080 | $ | (70,895 | ) | $ | 20,964 | $ | 42,053 | $ | 48,305 | |||||||
Fixed charges: |
||||||||||||||||||
Interest expense(2) |
$ | 12,875 | $ | 11,439 | $ | 14,281 | $ | 2,417 | $ | 29 | ||||||||
Capitalized interest |
5,154 | 4,757 | 689 | — | — | |||||||||||||
Portion of rentals representative of interest factor |
297 | 1,161 | 1,885 | 1,172 | — | |||||||||||||
Fixed charges |
$ | 18,326 | $ | 17,357 | $ | 16,855 | $ | 3,589 | $ | 29 | ||||||||
Ratio of earnings to fixed charges |
1.75 | (4.08 | ) | 1.24 | 11.72 | 1,665.69 | ||||||||||||
Excess of fixed charges over earnings |
$ | — | $ | 88,252 | $ | — | $ | — | $ | — | ||||||||
- (1)
- Years
ended December 31, 2006 through 2008 have been adjusted for the retrospective adoption of Financial Accounting Standards Board Accounting
Standards Codification™ 470-20, Debt with Conversion Options and Other Options, formerly provided under FASB Staff Position
No. APB 14-1, Accounting for Convertible Debt Instruments That May Be Settled in Cash Upon Conversion (Including Partial Cash Settlement
(FSP APB 14-1).
- (2)
- Includes amortization of debt discount and issue costs.
NOTE: The Ratio of Earnings to Fixed Charges should be read in conjunction with the Consolidated Financial Statements and related Notes and Management's Discussion and Analysis of Financial Condition and Results of Operations contained in United Therapeutics Corporation's Annual Report on Form 10-K for the year ended December 31, 2009.
United Therapeutics Corporation Ratio of Earnings to Fixed Charges (Unaudited)